Novavax (NVAX) Stock Statistics & Valuation Metrics

Novavax has a market cap or net worth of CHF1.25B. The enterprise value is $1.63B.

Novavax has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Novavax’s return on equity (ROE) is -3.45 and return on invested capital (ROIC) is 78.00%.

The current PE Ratio of Novavax is ―. Novavax’s PEG ratio is -0.00769.

In the last 12 months, Novavax had revenue of 1.12B and earned 440.30M in profits. Earnings per share was 2.72.

In the last 12 months, operating cash flow was -91.56M and capital expenditures -5.61M, giving a free cash flow of -97.17M billion.

Novavax pays an annual dividend of ―, resulting in a dividend yield of ―

Novavax upcoming earnings date is Aug 12, 2026, After Close (Confirmed).

Novavax as a current ratio of 2.13, with Debt / Equity ratio of -203.82%

In the past 12 months, Novavax has paid 1.86M in taxes.

Novavax EV to EBITDA ratio is 2.23, with an EV/FCF ratio of -4.38.

Novavax has CHF790.33M in cash and marketable securities with CHF295.06M in debt, giving a net cash position of CHF495.27M billion.

Gross margin is 84.64%, with operating margin of 50.14%, and net profit margin of 39.19%.

The average price target for Novavax is CHF9.50, which is 11.43% higher than the current price. The consensus rating is Hold